Substituted Bicyclic Compounds for Selective Mutant Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating polyglutamine-related neurodegenerative disorders, such as Huntington's disease and spinocerebellar ataxia type 3, lack specificity in reducing mutant protein levels and often affect wild-type proteins, leading to side effects and limited therapeutic efficacy.
Innovation Solution
A compound with a substituted bicyclic structure is used to selectively target and degrade mutant proteins, enhancing autophagy while minimizing impact on wild-type proteins, utilizing a compound of formula (I) and its derivatives to prepare medicaments for treating these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If low molecular weight compounds are used to control protein levels, then the level of mutant proteins can be reduced, but the method lacks specificity and affects wild-type proteins leading to side effects
Solution Approach 1:
The compound is designed to recognize and bind specifically to unique structural features of mutant polyQ proteins (such as expanded polyglutamine tracts, aggregation-prone regions, or specific conformational epitopes) while sparing wild-type proteins. This localized recognition ensures that only the pathological mutant form is targeted for degradation, eliminating side effects from wild-type protein reduction.
Solution Approach 2:
The approach segments the protein population into two distinct targets: mutant proteins with pathological features and wild-type proteins with normal structure. By designing compounds that recognize specific segments or features unique to mutant proteins (such as expanded polyQ tracts above a threshold length), the method achieves selective degradation without affecting wild-type counterparts.
2Productivity
If methods enhancing autophagy are used to increase protein degradation, then protein degradation ability is improved, but the method lacks selectivity
Solution Approach 1:
The low molecular weight compound acts as an intermediary that bridges the non-selective autophagy pathway and specific mutant protein targets. The compound binds to mutant proteins and recruits autophagy machinery specifically to mutant protein aggregates, thereby harnessing the high degradation capacity of autophagy while directing it selectively to mutant proteins rather than causing non-specific degradation of all proteins.
Data Source
AI summary
The present invention relates to use of a compound with a substituted bicyclic structure, a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotopic compound, metabolite or prodrug thereof in the preparation of a medicament for preventing or treating polyglutamine (polyQ) related disorders.